Allogene Therapeutics, Inc. (NASDAQ: ALLO)

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company that develops genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The company focuses on creating off the shelf therapies derived from healthy donors that can be administered to any patient, aiming to overcome the limitations of autologous cell therapies such as manufacturing delays and variable potency. Its pipeline includes product candidates targeting CD19 for large B cell lymphoma, CD70 for renal cell carcinoma, and a dual CD19/CD70 approach for autoimmune indications such as systemic lupus erythematosus.

Allogene Therapeutics generates revenue primarily through collaboration and licensing agreements with biopharmaceutical partners. The company has an exclusive agreement with Servier for the development and commercialization of its CD19 directed candidate cemacabtagene ansegedleucel in the United States, the European Union and the United Kingdom. It also holds licenses from Cellectis for TALEN based gene editing technology and from Arbor Biotechnologies for CRISPR based gene editing tools used in its oncology and autoimmune programs. Additionally, the company may receive milestone payments and research funding under these alliances.

Allogene Therapeutics positions itself as a leader in the emerging allogeneic CAR T field, competing with established autologous CAR T therapies from companies such as Kite Gilead, Novartis and Bristol Myers Squibb. Its competitive advantages stem from the off the shelf nature of its products, which could provide faster availability, broader patient access and more consistent manufacturing compared to patient specific approaches. The company also leverages its proprietary dagger technology to reduce reliance on lymphodepletion and improve persistence of infused cells, a feature not widely present among rivals.

The company serves patients with hematologic malignancies, solid tumors and autoimmune disorders through treatment centers and hospitals that administer its investigational therapies in clinical trials. While specific customer names are not disclosed, Allogene Therapeutics collaborates with partners such as Servier, Cellectis and Arbor Biotechnologies to advance its programs and may engage with additional pharmaceutical companies for future co development or licensing arrangements.